Date: 2014-05-13
Type of information: Development agreement
Compound: small molecule inhibitors in pain management therapy
Company: Orion Corporation (Finland) Jubilant Biosys (India)
Therapeutic area: CNS diseases
Type agreement: development
Action mechanism:
Disease: pain
Details: * On May 13, 2014, Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation, the largest pharmaceutical company in Finland, announced a path-breaking drug discovery collaboration to discover small molecule inhibitors in the neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit the large population of people with unmet needs in the pain management area. As per the terms of agreement, Jubilant’s extensive experience in drug discovery and pre-clinical development will be utilised by Orion to address pain management needs of Central Nervous System (CNS). Jubilant will offer integrated drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services. The research for the project, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (India) and some parts at Jubilant Discovery Center, USA.
Financial terms: Jubilant will receive research funding from Orion for delivering Hit, Lead Generation and Optimization milestone, according to a pre-defined research plan. Under the royalty based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.
Latest news:
